Lakefront Biotherapeutics (LKFT) Other Working Capital Changes (2018 - 2020)

Lakefront Biotherapeutics (LKFT) has reported Other Working Capital Changes for 11 consecutive years, with -$50.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Working Capital Changes rose 18.68% year-over-year to -$50.8 million; the TTM figure through Mar 2026 stood at $68.5 million (up 124.31% YoY), while the FY2025 annual figure was $53.0 million, changed N/A from the prior year.
• Other Working Capital Changes eased to -$50.8 million in Q1 2026 per LKFT's latest filing, from $256.6 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $298.8 million in Q1 2016 and bottomed at -$17.0 million in Q2 2017.
• Historically, Other Working Capital Changes has averaged $37.3 million across 5 years, with a median of $95825.6 in 2018.
• Annual changes were most pronounced in 2023 — Other Working Capital Changes slumped 47.76% — and 2024, when it soared 44.88%.
• Lakefront Biotherapeutics' Other Working Capital Changes stood at -$109.3 million in 2022, then plunged by 47.76% to -$161.6 million in 2023, then sank by 35.55% to -$219.0 million in 2024, then surged by 217.16% to $256.6 million in 2025, then sank by 119.79% to -$50.8 million in 2026.
• Business Quant data shows LKFT's Other Working Capital Changes at -$50.8 million in Q1 2026, $256.6 million in Q4 2025, and -$205.3 million in Q3 2025.